Zevra Therapeutics amends bylaws to address universal proxy rules and update stockholder meeting procedures

ZEVRA THERAPEUTICS, INC.

Board approved amended and restated bylaws effective February 22, 2024.
Amendments incorporate SEC universal proxy rules (Rule 14a-19) for director nominations.
Requires stockholders soliciting proxies to use a non-white proxy card.
Includes technical and conforming changes to reflect updates in Delaware General Corporation Law.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ZEVRA THERAPEUTICS, INC.: Amended and restated bylaws effective February 22, 2024 to address universal proxy rules, update stockholder nomination and proposal disclosure, and require proxy card color distinction (effective 2024-02-22).

Change: bylaw amendment
Effective: 2024-02-22

Exact text from the filing

On February 22, 2024, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) approved and adopted the Company’s amended and restated bylaws (the “Amended and Restated Bylaws”) which became effective the same day.

View on SEC.gov

Browse all governance changes →

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-005904

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.